Celltrion Is Latest To Settle Over Stelara

Deal With J&J Over CT-P43 Ustekinumab Biosimilar Offers Another 2025 Entry Date

 
• By David Wallace
  
Sprinter on starting blocks With 2025 text
Celltrion’s biosimilar is set to enter the market in 2025 • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Deals

More from Business